UroGen: Upcoming PDUFA, Some Concerns Remain
Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.
Investing19d
JELMYTO shows promise in long-term cancer treatment study
PRINCETON, N.J. - Recent findings from a study on UroGen Pharma Ltd.'s (NASDAQ: URGN) JELMYTO (mitomycin) for pyelocalyceal solution suggest its effectiveness in long-term disease control for ...
Business Wire19d
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper ...
The long-term study evaluated 56 patients who achieved complete response after treatment with JELMYTO from 15 high-volume academic and community centers and helps characterize how urologists are ...
Investing19d
JELMYTO shows promise in long-term cancer treatment study
PRINCETON, N.J. - Recent findings from a study on UroGen Pharma Ltd.'s (NASDAQ: URGN) JELMYTO (mitomycin) for pyelocalyceal solution suggest its effectiveness in long-term disease control for patients ...
Pharm Exec18d
Jelmyto Demonstrates Significant Recurrence-Free Survival Rate at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer
Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with Jelmyto. A majority of patients with low-grade upper tract urothelial ...
Hosted on MSN19d
JELMYTO shows promise in long-term cancer treatment study
In parallel, UroGen's FDA-approved treatment, JELMYTO, has demonstrated sustained effectiveness in treating low-grade upper tract urothelial cancer, with a median duration of response of 47.8 ...
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Target Price from Brokerages
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) has received an average recommendation of “Buy” from the six research ...